Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$4.86 -1.2%	$4.93	$3.61 ▼ $13.27	$53.89M	1.55	183,916 shs	27,941 shs
HOWL Werewolf Therapeutics	$1.23 -3.9%	$0.93	$0.60 ▼ $4.73	$55.20M	0.48	428,242 shs	378,012 shs
OTLK Outlook Therapeutics	$1.85 +2.8%	$1.48	$0.87 ▼ $9.25	$62.10M	0.39	771,309 shs	1.21 million shs
PHGE BiomX	$0.48 -35.0%	$0.55	$0.46 ▼ $4.43	$12.83M	1.51	82,239 shs	53,300 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	0.00%	+6.11%	-15.48%	-2.80%	-62.33%
HOWL Werewolf Therapeutics	0.00%	+6.96%	+35.96%	+7.89%	-76.21%
OTLK Outlook Therapeutics	0.00%	+15.63%	+19.35%	+30.28%	-73.83%
PHGE BiomX	0.00%	-6.43%	-16.52%	-25.81%	-88.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DTIL Precision BioSciences	3.8872 of 5 stars	3.5	2.0	0.0	4.6	1.7	1.7	0.6
HOWL Werewolf Therapeutics	3.1457 of 5 stars	3.5	1.0	0.0	0.0	3.3	5.0	0.6
OTLK Outlook Therapeutics	1.8292 of 5 stars	3.4	3.0	0.0	0.0	1.9	0.0	0.6
PHGE BiomX	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	3.00	Buy	$47.00	867.08% Upside
HOWL Werewolf Therapeutics	3.00	Buy	$8.33	577.51% Upside
OTLK Outlook Therapeutics	2.80	Moderate Buy	$10.20	451.35% Upside
PHGE BiomX	3.00	Buy	$21.00	4,275.00% Upside

Current Analyst Ratings Breakdown

Latest PHGE, DTIL, OTLK, and HOWL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/20/2025	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	PHGE BiomX	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/9/2025	HOWL Werewolf Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $6.00
4/4/2025	PHGE BiomX	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
3/28/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/19/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/12/2025	HOWL Werewolf Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
3/12/2025	HOWL Werewolf Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$51.14M	1.05	N/A	N/A	$4.53 per share	1.07
HOWL Werewolf Therapeutics	$1.14M	48.29	N/A	N/A	$3.08 per share	0.40
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.57) per share	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	-$61.32M	-$2.01	81.01	N/A	N/A	11.48%	-23.69%	-6.98%	7/30/2025 (Estimated)
HOWL Werewolf Therapeutics	-$37.37M	-$1.67	N/A	N/A	N/A	-578.80%	-58.83%	-38.45%	8/14/2025 (Estimated)
OTLK Outlook Therapeutics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-225.12%	8/13/2025 (Estimated)
PHGE BiomX	-$28.32M	-$0.85	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A

Latest PHGE, DTIL, OTLK, and HOWL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/15/2025	Q2 2025	OTLK Outlook Therapeutics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A
5/8/2025	Q1 2025	HOWL Werewolf Therapeutics	-$0.44	-$0.40	+$0.04	-$0.40	$0.30 million	N/A
3/26/2025	Q4 2024	DTIL Precision BioSciences	-$2.09	-$3.20	-$1.11	-$2.22	$4.28 million	$3.47 million
3/11/2025	Q4 2024	HOWL Werewolf Therapeutics	-$0.43	-$0.46	-$0.03	-$0.46	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.34	9.22	9.22
HOWL Werewolf Therapeutics	0.29	10.10	10.10
OTLK Outlook Therapeutics	N/A	0.32	0.64
PHGE BiomX	0.51	2.84	2.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
HOWL Werewolf Therapeutics	64.84%
OTLK Outlook Therapeutics	11.20%
PHGE BiomX	40.57%

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	4.50%
HOWL Werewolf Therapeutics	21.10%
OTLK Outlook Therapeutics	4.80%
PHGE BiomX	1.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	200	11.09 million	7.36 million	No Data
HOWL Werewolf Therapeutics	40	44.87 million	35.16 million	Optionable
OTLK Outlook Therapeutics	20	33.57 million	30.48 million	Optionable
PHGE BiomX	120	26.18 million	44.04 million	Not Optionable

PHGE, DTIL, OTLK, and HOWL Headlines

Recent News About These Companies

BiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 Conference

May 21, 2025 | nasdaq.com

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 19, 2025 | globenewswire.com

BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 15, 2025 | globenewswire.com

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

May 8, 2025 | globenewswire.com

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

April 18, 2025 | zacks.com

BiomX announces going concern qualification from independent audit

April 1, 2025 | markets.businessinsider.com

BiomX target adjusted to $21 from $2 at H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

April 1, 2025 | globenewswire.com

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

March 31, 2025 | globenewswire.com

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

March 25, 2025 | globenewswire.com

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

March 19, 2025 | globenewswire.com

BiomX reports “impressive” data in first bacteriophage trial

February 21, 2025 | pharmaphorum.com

BiomX regains compliance with NYSE American continued listing standards

December 17, 2024 | markets.businessinsider.com

BiomX shares hold Buy rating from H.C. Wainwright on Q3 results

November 17, 2024 | uk.investing.com

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

November 14, 2024 | globenewswire.com

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

November 12, 2024 | globenewswire.com

BiomX Announces a Mandatory Unit Separation

October 15, 2024 | globenewswire.com

BiomX Stock Gains From Favorable Study Data Presentation on BX004

September 20, 2024 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, DTIL, OTLK, and HOWL Company Descriptions

Precision BioSciences NASDAQ:DTIL

$4.86 -0.06 (-1.22%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$4.70 -0.16 (-3.21%)

As of 08:30 AM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Werewolf Therapeutics NASDAQ:HOWL

$1.23 -0.05 (-3.91%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.21 -0.02 (-1.63%)

As of 08:10 AM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Outlook Therapeutics NASDAQ:OTLK

$1.85 +0.05 (+2.78%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.84 -0.01 (-0.27%)

As of 08:36 AM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

BiomX NYSEMKT:PHGE

$0.48 -0.26 (-35.05%)

Closing price 05/30/2025 03:58 PM Eastern

Extended Trading

$0.49 +0.01 (+2.29%)

As of 08:15 AM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time